Understanding Stem Cell Transplant 2007
|
|
- つねとき さわなか
- 5 years ago
- Views:
Transcription
1 Understanding Stem Cell Transplant IMF International Myeloma Foundation Riverside Drive, Suite 206 North Hollywood, CA USA Telephone: CURE (2873) (USA & Canada) Fax: /07
2 David Vesole Brian Durie 2007, International Myeloma Foundation, North Hollywood, California
3 ? 4 5
4 M 4 M ISS 2 2M 3.5g/dl 2 3.5mg/dl 3.5 g/dl mg/dl g/dl 2 5.5mg/dl M ""
5
6 HLA "" HLA (MUD) (HLA) 100 " " VAD VDD IMF( )
7 36 50 PR 50% VGPR 90% CR ) VGPR CR VGPR CR VAD VGPR CR VGPR CR VGPR CR CR ) VGPR " "[] VGPR CR VGPR CR VGPR PR[] PR50% VGPR90% CR100%
8 PR()VGPR CR 50PR "" ""
9 Neupogen Neulasta Leukine [PBSC] 1) 2) 1) 2)
10 "Tylenol " 2 DMSO 10 CD34+ CD34+ kg 200 CD34+ CD34+ CD34+ 2 kg 400 CD
11 AMD-3100 ("Mozobil ") 200mg (mg/) {} DMSO
12 3 2,
13 4 36 QOL 24 25
14 2 6 2 VGPR CR "Quadramet " Sm-153 "" GVHD 4 GVHD 26 27
15 28 29
16 IMF IMF 30 31
17 , "" QOL
18
19 36 37
20 IMF 1 2 IMF. D. 75, ,000 20,000 IMF IMF 4 IMF 185,000 IMF IMF IMF 38 39
21 IMF IMF InfoPack IMF IMF 24 : CURE (2873) IMF IMF 100 IMF IMF Myeloma Minute BANK ON A CURE DNA ISS Myeloma Matrix IMF IMF Myeloma Today 40 41
22 DNA HLA (NMDP) 13 14g/dl 10g/dl CD34+ CD
23 CSF() "Neupogen" "Neulasta""Leukine" CR: CR CR ISS 20 M M M M M M PBSC "" PBSC PBSC CR CR 44 45
24 VGPR) 100 M Attal M, Harrousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335: Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood. 1998;92: Barlogie B, Jagannath S. Desikan KR< et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93: Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348: Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349: Fassas AB, Van Rhee F, Tricot G. Predicting long-term survival in multiple myeloma patients following autotransplants. Leuk Lymphoma. 2003;44: Blade J. Transplantation for multiple myeloma: who, when, how often? High-dose therapy in multiple myeloma. Blood. 2003;15: Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and menatopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354: Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med. 2006;354: Barlogie B, Tricot G. Complete response in myeloma: a Trojan horse? Blood. 2006;108:2134. IMF IMF
untitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
More information原 著 International Journal of Myeloma 3(1): 47 54, 2013 日本骨髄腫学会 多発性骨髄腫に対する melphalan 大量投与を用いた tandem 自家移植の有用性 牟田毅 1, 上村智彦 4, 宮本敏浩 1, 大野裕樹 3, 平安山知子 1, 加
原 著 International Journal of Myeloma 3(): 47 54, 23 日本骨髄腫学会 多発性骨髄腫に対する melphalan 大量投与を用いた tandem 自家移植の有用性 牟田毅, 上村智彦 4, 宮本敏浩, 大野裕樹 3, 平安山知子, 加藤光次, 竹中克斗, 岩崎浩己, 藤﨑智明 2, 衛藤徹也 5, 赤司浩一, 福岡 BMT グループ 多発性骨髄腫に対する
More information10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
More information日赤 No.35☆/7.河相
2 64 2 Mucosa-Associated Lymphoid TissueMALT T γ- 1 Key words T 1 2 64 47 54 60 MALT 63 T MALT 6062-8 63 1 T MALT 63 CHOP 2 35 28 30 28 75 μg 200 mg 20 mg 200 mg 400 mg/80 mg 2 35 mg 1 2 150 mg 200 mg
More informationTable 1 Laboratory data on admission Fig. 1 Visual finding of the chest
A Case of Klinefelter Syndrome Associated with Mediastinal Germ Cell Tumor Presenting with a Prominent Gynecomastia Tomomi HARAI,*" Hiromichi TANEICHI,*1 Hisano SAKAKC Keiko NOMURA,*2 Hirokazu KANEGANE*2
More information051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
More informationKey words: pure red cell anemia, allogeneic bone marrow transplantation.
Complete Recovery of Hemopoiesis Following Bone Marrow Transplantation in a Patient with Unresponsive Congenital Pure Red Cell Anemia Masami SHIMADA, Hideo MUGISHIMA, Mitsuhiko HARA, Masahiro MISAWA, Hideo
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More informationuntitled
Shinichiro Okamoto MD, PhD Keio University School of Medicine Tokyo Japan vincristine) Berberidaceae etoposide VP-16) MRD 10 12 PCR 10 10 10 8 10 6 10 4 10 2 ( CR) ( CR) AML Study n Ind Consol % 3
More information日本内科学会雑誌第105巻第7号
トピックス Ⅵ. 多発性骨髄腫に対する標準治療 多発性骨髄腫に対する標準治療 要旨 多発性骨髄腫 (multiple myeloma:mm) の治療成績は, 新規薬剤の導入により深い奏効が得られるようになったことや, 再発難治例にも有効な治療薬が登場したことにより改善している. 若年者の初回標準治療は, 新規薬剤を組み込んだ寛解導入療法に続く自家移植併用大量化学療法である. この10 年の骨髄腫の治療成績向上は,
More information食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
More informationC/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
More information報告書
1 2 3 4 5 6 7 or 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2.65 2.45 2.31 2.30 2.29 1.95 1.79 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 60 55 60 75 25 23 6064 65 60 1015
More informationuntitled
1) American College of Surgeons:Advanced Trauma Life Support Course Manual. American College of Surgeons 1997;103-112 24 2) American Society of Anesthesiologists Task Force:Practice guideline for blood
More information取扱説明書 [F-02F]
F-02F 4. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d a b cd 9 e a b c d e 20 2 22 ab a b 23 a b 24 c d e 25 26 o a b c p q r s t u v w d h i j k l e f g d m n a b c d e f g h i j k l m n x 27 o
More information.K.C.h...C...ren
4 quality of life QOL QOL QOL 3 QOL 19 mmhg 16 mmhg 14 mmhg 1 2 7 20 30 QOL QOL QOL QOL QOL QOL QOL 4 1 1 1 2 1 2 3 1 2 4 2 2 1 2 2 2 2 1 2 3 QOL 3 2 1 1 5 1 1 2 1 Abraham Wise 1 Nd YAG 2 1 200 500 200
More information取扱説明書 [F-06E]
F-06E 3.6 2 3 4 5 6 7 8 9 0 2 3 4 5 6 a b c d a b c d 7 a b cd e a b c 8 d e 9 20 a b b a a b 2 22 b a c 23 d 24 a b c d e f g h l m n o p i j k ku v w q r s t x y a b c d e f g h i j k l m n o p q
More information! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
More information橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
More information2009年133巻3号3月号.indb
Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine
More information< D F97D58FB08C8C D31305F33368BB388E78D F94A82E6D6364>
臨床血液 第 75 回日本血液学会学術集会リンパ系腫瘍 :MM EL-36 ガイドライン ( 標準治療 ) 多発性骨髄腫ガイドライン 畑 裕之 Key words : Multiple myeloma, Guideline, Treatment はじめに多発性骨髄腫に対する多くの新薬の登場は, 飛躍的な治療選択肢の増加を実現したが, 適切な治療選択に悩む状況をもたらしている この状況を整理すべく,National
More information1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
More information骨髄異形成症候群に対する 同種造血幹細胞移植の現状と課題
第 36 回造血幹細胞移植委員会 (H25.2.4) 資料 5 第 36 回厚生科学審議会疾病対策部会造血幹細胞移植委員会 日本造血細胞移植学会 (JSHCT) 移植医療の現場からの提言 日本造血細胞移植学会理事長 岡本真一郎 我が国における非血縁者間造血幹細胞移植数 2000 1800 1600 1400 1200 1000 800 600 400 200 非血縁者間骨髄移植非血縁者間臍帯血移植
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More information32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
More informationM1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
More information病態と治療のあらまし
Concise Review of the Disease and Treatment Options Multiple Myeloma Cancer of the Bone Marrow International Myeloma Foundation 2007 GM 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. (1) (2) (3) (4)
More informationuntitled
1991 1) 4 20 2) 5 4 3) 5 5 4) 5 9 5) 5 15 6) 10 15 7) 2 10 1000 11 27 8) 12 25 1992 9) 4 10) 9 10 11) 10 4 12) 10 9 13) 10 9 14) 2 22 15) 2 25 16) 3 17)!? 3 3 18) 3 3 1993 19) 4 11 20) 8 14 21) 10 5 22)
More information取扱説明書 [F-05E]
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
More informationqxd
BD FACS TM Review Vol.7 BD FACSAria TM BD FACSAria FACS HLA-FACS Key words: HLA FACS 1988 Eliane Glukmann Fanconi 1 5 10% 30% mixed chimerism HLA human leukocyte antigen HLAFACS fluorescence activated
More information1 2 1 3 2 4 22 NPO PR NPO NPO 22 10 4 2,000kg 1kg 5 2 1 4,000 20,000 26 33 27 24 3 19 24 3 4 3 4 3 () 34 3 4 5 23 3 17 23 20 30 1 1 877g/ 3 24 3 1 1 28 897g/ 33 850g/ 22 23 30 1 1 510g/ 22 23 3 24
More information2 角南一貴 日本造血細胞移植学会雑誌第 4 巻第 1 号,2015 Table 1.Reports of reduced intensity stem cell transplantation for multiple myeloma 5,6,12 16 Author n RIC agvhd cg
総説 report Case 多発性骨髄腫に対する同種造血幹細胞移植 Pleurisy as a novel clinical manifestation associated with human 角南一貴 herpesvirus 6 after unrelated cord blood transplantation 独立行政法人国立病院機構岡山医療センター 血液内科 Hiroshi Arima,
More information3675-433897418-1.pdf
A : : : : : : : : : : PR PR NHK 2 PR PR 3 1954 7 4 5 9 12,000 12 100 2 2 11 4 5 6 7 / PR 8 9 10 11 1952 ( ) 2008 2009 2012 NHK km m m 12 m km km kg kg 13 % 14 15 1959 5 20 8 17100kg 400kg How much? 60
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More information本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
More information要望番号 ;Ⅱ-183 未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者学会 ( 該当する ( 学会名 ; 日本感染症学会 ) ものにチェックする ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 1 位 ( 全 8 要望中 ) 要望する医薬品
未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者学会 ( 該当する ( 学会名 ; 日本感染症学会 ) ものにチェックする ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 1 位 ( 全 8 要望中 ) 要望する医薬品 要望内容 成分名 ( 一般名 ) 販売名 会社名 国内関連学会 未承認薬 適応 外薬の分類 ( 該当するものにチェックする )
More information164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10
163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination
More information1 2 3 4 1 3 4 2 5 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 21 24 25 26 27 28 29 30 31 32 33 34 9 35 36 14 9 14 15 37 38 39 35 1 519 4 NPO 40 41 9 10 4 (9 Or10 ) PR 3 21 21 42 2 10 43 44 15
More informationVENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
More information_06.indd
30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,
More informationRinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
More informationŁ½’¬24flNfix+3mm-‡½‡¹724
571 0.0 31,583 2.0 139,335 8.9 310,727 19.7 1,576,352 100.0 820 0.1 160,247 10.2 38,5012.4 5,7830.4 9,5020.6 41,7592.7 77,8174.9 46,425 2.9 381,410 24.2 1,576,352 100.0 219,332 13.9 132,444 8.4 173,450
More informationuntitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
More informationSBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
More information16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57
Major Histocompatibility Complex 2018; 25 (1): 56 82 抄録集 16 2018 3 3 7 2 4 43 TEL 06 6962 7001 594 1101 840 TEL 0725 56 1220 56 16 MHC 2018; 25 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 3 13:00 13:10 2 3
More information胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
More information03慢性骨髄性白血病CML.indd
慢* 59 病CML略語一覧 Ⅰ クリニカルクエスチョン一覧 Ⅱ 略語一覧 慢性骨髄性白血病 CML CQ 1 小児 CML の標準的治療は何か CQ 2 小児 CML 治療における造血幹細胞移植の役割は何か CML (Chronic Myelocytic Leukemia, 慢性骨髄性白血病 ) TKI (Tyrosine Kinase Inhibitor, チロシンキナーゼ阻害薬 ) CHR (Complete
More informationuntitled
twatanab@oncoloplan.com http://www.oncoloplan.com I II - III IV Fig 3. Survival curves overall and according to response Bruzzi, P. et al. J Clin Oncol; 23:5117-5125 25 Copyright merican Society of Clinical
More informationuntitled
1. 1 2. 2 3.,1995 3 223119 3.1,, 4 3.2 NTT,2003 5 mile,2003 4.,, 6 , 2001 22 126 7 9 34 22 22 8 (139) 8 6. 6.1,,,,,, 9 6.2a Who What Whom When How Where 3 4 5 4 8 8 4, 7 6,,,, 2 or 3 6.2NGO NGO Who What
More information....
2030 2 Vol. 22 No. 32000 1/2 EE F FAF 60E 1970 40 25FIP 1995 503cx 60 10M5 Vol. 22 No. 32000 3 carpal tunnel syndrome entrapment neuropathy cm 4 Vol. 22 No. 32000 5 Vol. 22 No. 32000 10 2- microglobulin
More information83
Candida sppmssa Haemophilus influenzae consolidation consolidation consolidation consolidation consolidation consolidation knuckle sign Westermark sign Hampton s hump Borchardt enteropathy-associated
More information268 LSG 図 Lee ABCD 表 1 4 Age BMI C Duration Still DiaRem 表 1 4 HbA1c Ⅱ 対象と方法 1 17 LSG 6 3 Excess Weight Loss EWL BMI 25 kg/m 2 Hb
52 5 18 1 267 原著 ( 臨床研究 ) LSG ABCD DiaRem LSG 3 93.1 1 7.8 CR37.5 PR33.3 1 ABCD 5 DiaRem 12 LSG ABCD DiaRem LSG 腹腔鏡下スリーブ状胃切除術,ABCD スコア,DiaRem スコア Ⅰ はじめに Bariatric Surgery 2 1 metabolic surgery 2 ABCD 2
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More information10 年相対生存率 全患者 相対生存率 (%) (Period 法 ) Key Point 1 の相対生存率は 1998 年以降やや向上した 日本で
151 10 年相対生存率 全患者 相対生存率 (%) 82 76 79 61 60 53 52 51 46 1993 1997 1998 2001 2002 2006 2002 2006 (Period 法 ) 44 40 43 Key Point 1 の相対生存率は 1998 年以降やや向上した 日本でパクリタキセル カルボプラチン併用療法が標準治療となった時期と一致する 0 1 2 3 4 5
More informationMicrosoft Word - Ⅱ-43.doc
未承認薬 適応外薬の要望 ( 別添様式 1) 1. 要望内容に関連する事項要望者 ( 該当する 学会ものにチェ ( 学会名 ; 日本造血細胞移植学会 ) ックする ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 7 位 ( 全 14 薬剤要望中 ) 要望する医薬品 要望内容 成分名 ( 一般名 ) 販売名 会社名 国内関連学会 未承認薬 適応外薬の分類 ( 該当するものにチェックする
More informationDetection methods of minimal residual disease and their prognostic value in patients with malignant hematological diseases はじめに (m
92 124 3 92 96 2015 Detection methods of minimal residual disease and their prognostic value in patients with malignant hematological diseases はじめに (minimal residual disease: MRD) MRD MRD ( 1) MRD PCR
More informationuntitled
2008/04/27 1. 1 2 staticdynamics etc 3 Hedberg A, Carlberg EB, Forssberg H, Hadders-Algra M. Development of postural adjustments in sitting position during the first half year of life. Dev Med Child Neurol.
More information形質細胞性白病に対するボルテゾミブ ドキソルビシン デキサメタゾン併用療法 緒 言 形質細胞性白病は多発性骨髄腫の一亜型と考えられて は当院初診時9歳の女性 2008年8月ごろから階段昇 いるが 約10%のに髄外病変を伴うなど臨床像が異な 降時の呼吸苦があったため2008年10月日近医で液検査を り
洛和会病院医学雑誌 Vol.22 90 94, 2011 形質細胞性白病に対するボルテゾミブ ドキソルビシン デキサメタゾン併用療法 洛和会音羽病院 高松 液内科 輝行 洛和会音羽病院 安井 病理 寛 Combination chemotherapy with bortezomib, doxorubicin and dexamethasone for plasma cell leukemia Department
More informationuntitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
More information7) G. N., A. A. Sondore et al.: The Use of Hyperbaric Oxygenation in Intensive Therapy of Patients with Liver Damage. VI Int. Cong. HBO Medicine, Moscow, Sept 2 `6:341, 1981 8) J. J. Moder, M. D.: Phagocytic
More informationsick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More information2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
More informationKey words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
More informationPTSD 17
- - 3 11 3 18 21 3 11 DMAT 72 3 14 PTSD 17 7 24 2 9 2000 2 3 1 5000 2 3 4 14 200 1 2 DMAT DMAT DMAT 3 4 30 70 13 4 5 6 3 4 6 81 DNA DNA DNA 23 1 2 4 2 3 5 25 4 6 10 4 2 4 1 3 2 1 3 1 3 with you forever
More information14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=
DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...
More informationMajor Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128
Major Histocompatibility Complex 2018; 25 (: 128 138 抄録集 2018 4 14 A 3 128 MHC 2018; 25 ( HLA 2013 10.5 10 8 12 10 8 2016 CD34 + HLA NC 10 8 CD34 + CD34 + 10 6 NC10.5 2013.Apr 2014.Mar NC11 2014.Apr 2016.Jun
More information-. -. CD Threshold Noise Discrimination CD CDbight+ CDdim CD は
CD34 JCCLS H3-P V1.0 Report of the Hematology Standardization Committee Guidelines for CD34+ Cell Determination by Flow CytometryJCCLS H3-P V1.0 日本臨床検査標準協議会血液検査標準化検討委員会フローサイトメトリーワーキンググループ Japanese Committee
More information17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2
1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)
More information[A](2): [B](4): DNA [B] [B](4):
3 [A](2): 7 6 19.4 16.7 [A] 0 0.0 1 2.8 1 2.8 13 [A](1): 36.1 1974 1 3.0 2 5.6 1975 1 3.0 2 5.6 1980 1 3.0 4 11.1 1990 1 3.0 0 0.0 1993 1 3.0 36 100.0 1994 1 3.0 1999 1 3.0 [A](2): 2000 1 3.0 2001 5 15.2
More informationBUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
More information<8DD AA97A3834C B BF8A69838A C8EA E786C7378>
ST-01738 ErythroClear Red Blood Cell Depletion Reagent kit 臍帯血 2 ml 用 17,000 13,600 ST-01739 ErythroClear Red Blood Cell Depletion kit 臍帯血 2 ml 用 475,000 380,000 ST-07801 Lymphoprep 250 ml 17,000 13,600
More information取扱説明書 [F-02F]
F-02F 3. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d 9 a b cd e a b c d e 20 2 22 ab a b 23 24 a c b 25 d e 26 o a b c p q r s t u d h i j k l e f g d m n a b c d e f g h i j k l m n v 27 o P P
More information17 17 17 17 11 21 28 1 24 12 36 2,000 2 22 11 3.67 3.38 22 2.97 21 10 1.7 1.12 22 10 13 2.75 11 10 15 24 10 12 14 3 17 17 2006 4 17 10 24 12 17 5 15 17 17 11 40 6 17 40 17 11 7 24 17 24 17 8 40 17 17 9
More informationPowerPoint Presentation
2 9/ 3 3 9/ 9 4 5 , PR () 6 ,,, (11) 7 PR 8 9 10 11 TEL. 106 8/131512/291/3 TEL. 107 12/291/3 12 http://www.f-turn.jp/ 13 21 4 21 14 200910 U 200911 U 200911 20102 15 20102 PR 20103 20103 16 20103 20104
More informationuntitled
,337 37 35 0,349,09 35 55 988 3 0 0 3,387 7 90 0,369,46 5 57 5 0 90 38 8,369 3 4 5 6 7 8 9 0 3 4 5 6 7 8 9 0 3 4 5 6 8 9 30 3 3 5,400 7,00 9,000 0,800,600 4,400 6,00 8,000 9,800,600 3,400 5,00 7,000 8,800
More information